Serum immune-activation potency and response to anti-TNF-α therapy in Crohn's disease

作     者：Hanne Rintamki Taina Sipponen Harri M Salo Outi Vaarala Kaija-Leena Kolho 

作者机构：Division of GastroenterologyHospital for Children and Adolescents and Helsinki University Central HospitalUniversity of Helsinki Department of MedicineDivision of GastroenterologyHelsinki University Central HospitalUniversity of Helsinki Immune Response UnitDepartment of Vaccination and Immune ProtectionNational Institute for Health and Welfare 

出 版 物：《World Journal of Gastroenterology》 (世界胃肠病学杂志（英文版）)

年 卷 期：2010年第16卷第46期

页      面：5845-5851页

核心收录：

学科分类：1002[医学-临床医学] 100201[医学-内科学(含：心血管病、血液病、呼吸系病、消化系病、内分泌与代谢病、肾病、风湿病、传染病)] 10[医学] 

基　　金：Supported by The Finnish Cultural Foundation the Finnish Pediatric Research Foundation the Pivikki and Sakari Sohlberg Foundation the Helsinki University Central Hospital Grant the Orion-Farmos Research Foundation the Maryand George C Ehrnrooth Foundation 

主　　题：Crohn’s disease endoscopic index of severity Forkhead transcription factor 3 Glucocorticoid-induced tumour necrosis factor receptor Infliximab Inflammatory bowel disease 

摘      要：AIM:To study whether immune-activation stage in serum of adult Crohn s disease (CD) patients correlates with disease activity and with treatment response to antitumor necrosis factor-α (TNF-α) ***:Serum samples were obtained from 15 adult CD patients introduced to anti-TNF-α *** individual stage of immune activation was studied applying our new in vitro assay,in which target cells (donor derived peripheral blood mononuclear cells) were cultured with patient serum and the T-cell activation induced by the patient serum was studied using a panel of markers for effector [interferon γ (IFNγ),interleukin (IL)-5] and regulatory T-cells [forkhead transcription factor 3 (FOXP3) and glucocorticoid-induced tumour necrosis factor receptor (GITR)].The endoscopic disease activity was assessed with the Crohn s disease endoscopic index of severity (CDEIS) before and 3 mo after therapy with an anti-TNF-α ***:Low induction of FOXP3 and GITR in target cells cultured in the presence of patient serum was associated with high disease activity *** assessed before therapy (r=-0.621,P=0.013 and r=-0.625,P=0.013,respectively).FOXP3 expression correlated inversely with pre-treatment erythrocyte sedimentation rate (r=-0.548,P=0.034).Low serum induced FOXP3 (r=-0.600,P=0.018) and GITR (r=-0.589,P=0.021) expression and low IFNγ secretion from target cells (r =-0.538,P=0.039) associated with treatment response detected as a decrease in ***:The immune-activation potency in the patient serum prior to anti-TNF-α therapy reflected intestinal inflammation and the therapeutic response.